Copper prescription in pregnancy

Evaluating the effect of copper supplement during pregnancy on premature and pregnancy outcome

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201008112624N7

Enrollment

200

Registered

2010-11-16

Start date

2010-10-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pregnancy outcome. Pregnancy, childbirth and the puerperium

Interventions

Intervention 1: Intervention group: Copper tablets, 1000 mg per day from 16th week of pregnancy up to delivery. Intervention 2: Control group: placebo tablets, from 16th week of pregnancy up to delive

Prevention

Placebo

Intervention group: Copper tablets, 1000 mg per day from 16th week of pregnancy up to delivery

Control group: placebo tablets, from 16th week of pregnancy up to delivery

Eligibility

Sex/Gender

Female

Age

18 Years to 35 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: nuliparity, age between 18-35, second trimester of pregnancy, and having written consent. Exclusion criteria: multiple pregnancy, history of any systemic disorders or drug use except iron supplement, known copper sensitivity, polyhydramnios, fetal death, fetal anomalies, smoking, alcohol consumption and drug abuse.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Preterm premature rupture of membranes and premature rupture of membranes. Timepoint: 9 months. Method of measurement: questionnaire.	—

Secondary

Measure	Time frame
Pregnancy outcome. Timepoint: 9 months. Method of measurement: questionnaire.;Birth weight. Timepoint: Delivery. Method of measurement: questionnaire.;Placental abruption, placenta previa, hemorrhage during pregnancy. Timepoint: 9 months. Method of measurement: questionnaire.;Anemia. Timepoint: 9 months. Method of measurement: Hemoglobin.;Preterm labor. Timepoint: 9 months. Method of measurement: questionnaire.;Preeclampsia. Timepoint: 9 months. Method of measurement: questionnaire.;Drug adverse effects. Timepoint: 9 months. Method of measurement: questionnaire.;Infection. Timepoint: 9 months. Method of measurement: questionnaire.	—

Measure

Time frame

Pregnancy outcome. Timepoint: 9 months. Method of measurement: questionnaire.;Birth weight. Timepoint: Delivery. Method of measurement: questionnaire.;Placental abruption, placenta previa, hemorrhage during pregnancy. Timepoint: 9 months. Method of measurement: questionnaire.;Anemia. Timepoint: 9 months. Method of measurement: Hemoglobin.;Preterm labor. Timepoint: 9 months. Method of measurement: questionnaire.;Preeclampsia. Timepoint: 9 months. Method of measurement: questionnaire.;Drug adverse effects. Timepoint: 9 months. Method of measurement: questionnaire.;Infection. Timepoint: 9 months. Method of measurement: questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Kashanian

Iran University of Medical Sciences

maryamkashanian@yahoo.com+98 21 5563 3244

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026